Your browser doesn't support javascript.
loading
Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model.
Pais, Gwendolyn M; Liu, Jiajun; Avedissian, Sean N; Hiner, Danielle; Xanthos, Theodoros; Chalkias, Athanasios; d'Aloja, Ernesto; Locci, Emanuela; Gilchrist, Annette; Prozialeck, Walter C; Rhodes, Nathaniel J; Lodise, Thomas P; Fitzgerald, Julie C; Downes, Kevin J; Zuppa, Athena F; Scheetz, Marc H.
Afiliação
  • Pais GM; Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.
  • Liu J; Midwestern University, Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA.
  • Avedissian SN; Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.
  • Hiner D; Midwestern University, Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA.
  • Xanthos T; Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.
  • Chalkias A; Midwestern University, Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA.
  • d'Aloja E; Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.
  • Locci E; School of Medicine, European University Cyprus, Nicosia, Cyprus.
  • Gilchrist A; Department of Anesthesiology, University of Thessaly, Larisa, Greece.
  • Prozialeck WC; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Rhodes NJ; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Lodise TP; Midwestern University, Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA.
  • Fitzgerald JC; Department of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.
  • Downes KJ; Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA.
  • Zuppa AF; Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.
  • Scheetz MH; Midwestern University, Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA.
J Antimicrob Chemother ; 75(5): 1228-1236, 2020 05 01.
Article em En | MEDLINE | ID: mdl-32011685
ABSTRACT

BACKGROUND:

Vancomycin and piperacillin/tazobactam are reported in clinical studies to increase acute kidney injury (AKI). However, no clinical study has demonstrated synergistic toxicity, only that serum creatinine increases.

OBJECTIVES:

To clarify the potential for synergistic toxicity between vancomycin, piperacillin/tazobactam and vancomycin + piperacillin/tazobactam treatments by quantifying kidney injury in a translational rat model of AKI and using cell studies.

METHODS:

(i) Male Sprague-Dawley rats (n = 32) received saline, vancomycin 150 mg/kg/day intravenously, piperacillin/tazobactam 1400 mg/kg/day intraperitoneally or vancomycin + piperacillin/tazobactam for 3 days. Urinary biomarkers and histopathology were analysed. (ii) Cellular injury was assessed in NRK-52E cells using alamarBlue®.

RESULTS:

Urinary output increased from Day -1 to Day 1 with vancomycin but only after Day 2 for vancomycin + piperacillin/tazobactam-treated rats. Plasma creatinine was elevated from baseline with vancomycin by Day 2 and only by Day 4 for vancomycin + piperacillin/tazobactam. Urinary KIM-1 and clusterin were increased with vancomycin from Day 1 versus controls (P < 0.001) and only on Day 3 with vancomycin + piperacillin/tazobactam (P < 0.001, KIM-1; P < 0.05, clusterin). The histopathology injury score was elevated only in the vancomycin group when compared with piperacillin/tazobactam as a control (P = 0.04) and generally not so with vancomycin + piperacillin/tazobactam. In NRK-52E cells, vancomycin induced cell death with high doses (IC50 48.76 mg/mL) but piperacillin/tazobactam did not, and vancomycin + piperacillin/tazobactam was similar to vancomycin.

CONCLUSIONS:

All groups treated with vancomycin demonstrated AKI; however, vancomycin + piperacillin/tazobactam was not worse than vancomycin. Histopathology suggested that piperacillin/tazobactam did not worsen vancomycin-induced AKI and may even be protective.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vancomicina / Injúria Renal Aguda Tipo de estudo: Observational_studies / Prognostic_studies Limite: Animals Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vancomicina / Injúria Renal Aguda Tipo de estudo: Observational_studies / Prognostic_studies Limite: Animals Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos